Radiofrequency ablation of pulmonary metastases from sarcoma

single-center retrospective evaluation of 46 patients

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: This retrospective, single-center study evaluated radiofrequency (RF) ablation for pulmonary metastases of sarcoma. Materials and methods: Forty-six patients with sarcoma (144 pulmonary metastases) underwent 88 RF ablation sessions. Data regarding local tumor progression, efficacy, procedural adverse events (AEs; National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0), overall survival (OS), and OS-associated prognostic factors were retrospectively evaluated using univariate analyses. Results: Local progression occurred in 22 of 144 tumors (15.3%). Primary and secondary efficacy rates were 83.5 and 90.0% at 1 year and 76.3 and 81.4% at 2 years, respectively. Seventy-three grade 1 AEs, 33 grade 2 AEs, and no grade ≥ 3 AEs were observed. Twenty-eight patients (60.9%) remained alive and 18 died, yielding 1-, 2-, and 3-year OS rates of 80.6, 70.1, and 47.1% (median survival time, 31.7 months). Univariate analysis revealed extrapulmonary metastasis (P = 0.005), noncurative RF ablation (P = 0.009), and a post-RF ablation disease-free interval of ≤12 months (P = 0.015) as significant negative prognostic factors. Conclusion: RF ablation is safe, offers good local control, and may be a viable treatment option for pulmonary metastasis of sarcoma.

Original languageEnglish
Pages (from-to)61-67
Number of pages7
JournalJapanese Journal of Radiology
Volume35
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Sarcoma
Neoplasm Metastasis
Lung
Survival
National Cancer Institute (U.S.)
Terminology
Neoplasms
Survival Rate
Therapeutics

Keywords

  • Lung metastasis
  • Radiofrequency ablation
  • Sarcoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{75deed68b9af42e1ab972dfb911d0d1f,
title = "Radiofrequency ablation of pulmonary metastases from sarcoma: single-center retrospective evaluation of 46 patients",
abstract = "Purpose: This retrospective, single-center study evaluated radiofrequency (RF) ablation for pulmonary metastases of sarcoma. Materials and methods: Forty-six patients with sarcoma (144 pulmonary metastases) underwent 88 RF ablation sessions. Data regarding local tumor progression, efficacy, procedural adverse events (AEs; National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0), overall survival (OS), and OS-associated prognostic factors were retrospectively evaluated using univariate analyses. Results: Local progression occurred in 22 of 144 tumors (15.3{\%}). Primary and secondary efficacy rates were 83.5 and 90.0{\%} at 1 year and 76.3 and 81.4{\%} at 2 years, respectively. Seventy-three grade 1 AEs, 33 grade 2 AEs, and no grade ≥ 3 AEs were observed. Twenty-eight patients (60.9{\%}) remained alive and 18 died, yielding 1-, 2-, and 3-year OS rates of 80.6, 70.1, and 47.1{\%} (median survival time, 31.7 months). Univariate analysis revealed extrapulmonary metastasis (P = 0.005), noncurative RF ablation (P = 0.009), and a post-RF ablation disease-free interval of ≤12 months (P = 0.015) as significant negative prognostic factors. Conclusion: RF ablation is safe, offers good local control, and may be a viable treatment option for pulmonary metastasis of sarcoma.",
keywords = "Lung metastasis, Radiofrequency ablation, Sarcoma",
author = "Takuya Sato and Toshihiro Iguchi and Takao Hiraki and Hideo Gobara and Hiroyasu Fujiwara and Jun Sakurai and Yusuke Matsui and Toshiharu Mitsuhashi and Junichi Sou and Shinichi Toyooka and Susumu Kanazawa",
year = "2017",
month = "2",
day = "1",
doi = "10.1007/s11604-016-0601-z",
language = "English",
volume = "35",
pages = "61--67",
journal = "Japanese Journal of Radiology",
issn = "1867-1071",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Radiofrequency ablation of pulmonary metastases from sarcoma

T2 - single-center retrospective evaluation of 46 patients

AU - Sato, Takuya

AU - Iguchi, Toshihiro

AU - Hiraki, Takao

AU - Gobara, Hideo

AU - Fujiwara, Hiroyasu

AU - Sakurai, Jun

AU - Matsui, Yusuke

AU - Mitsuhashi, Toshiharu

AU - Sou, Junichi

AU - Toyooka, Shinichi

AU - Kanazawa, Susumu

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Purpose: This retrospective, single-center study evaluated radiofrequency (RF) ablation for pulmonary metastases of sarcoma. Materials and methods: Forty-six patients with sarcoma (144 pulmonary metastases) underwent 88 RF ablation sessions. Data regarding local tumor progression, efficacy, procedural adverse events (AEs; National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0), overall survival (OS), and OS-associated prognostic factors were retrospectively evaluated using univariate analyses. Results: Local progression occurred in 22 of 144 tumors (15.3%). Primary and secondary efficacy rates were 83.5 and 90.0% at 1 year and 76.3 and 81.4% at 2 years, respectively. Seventy-three grade 1 AEs, 33 grade 2 AEs, and no grade ≥ 3 AEs were observed. Twenty-eight patients (60.9%) remained alive and 18 died, yielding 1-, 2-, and 3-year OS rates of 80.6, 70.1, and 47.1% (median survival time, 31.7 months). Univariate analysis revealed extrapulmonary metastasis (P = 0.005), noncurative RF ablation (P = 0.009), and a post-RF ablation disease-free interval of ≤12 months (P = 0.015) as significant negative prognostic factors. Conclusion: RF ablation is safe, offers good local control, and may be a viable treatment option for pulmonary metastasis of sarcoma.

AB - Purpose: This retrospective, single-center study evaluated radiofrequency (RF) ablation for pulmonary metastases of sarcoma. Materials and methods: Forty-six patients with sarcoma (144 pulmonary metastases) underwent 88 RF ablation sessions. Data regarding local tumor progression, efficacy, procedural adverse events (AEs; National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0), overall survival (OS), and OS-associated prognostic factors were retrospectively evaluated using univariate analyses. Results: Local progression occurred in 22 of 144 tumors (15.3%). Primary and secondary efficacy rates were 83.5 and 90.0% at 1 year and 76.3 and 81.4% at 2 years, respectively. Seventy-three grade 1 AEs, 33 grade 2 AEs, and no grade ≥ 3 AEs were observed. Twenty-eight patients (60.9%) remained alive and 18 died, yielding 1-, 2-, and 3-year OS rates of 80.6, 70.1, and 47.1% (median survival time, 31.7 months). Univariate analysis revealed extrapulmonary metastasis (P = 0.005), noncurative RF ablation (P = 0.009), and a post-RF ablation disease-free interval of ≤12 months (P = 0.015) as significant negative prognostic factors. Conclusion: RF ablation is safe, offers good local control, and may be a viable treatment option for pulmonary metastasis of sarcoma.

KW - Lung metastasis

KW - Radiofrequency ablation

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84995745226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995745226&partnerID=8YFLogxK

U2 - 10.1007/s11604-016-0601-z

DO - 10.1007/s11604-016-0601-z

M3 - Article

VL - 35

SP - 61

EP - 67

JO - Japanese Journal of Radiology

JF - Japanese Journal of Radiology

SN - 1867-1071

IS - 2

ER -